DISCERN™ is the most accurate, least invasive and most cost effective test for identifying Alzheimer’s Disease (Rockville, MD) October 15, 2018 – NeuroDiagnostics, LLC, a privately held neurological diagnostics company, announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to NeuroDiagnostics’ DISCERNTM multiple biomarker test for Alzheimer’s Disease. If approved, …
Input your search keywords and press Enter.
Recent Comments